Revenue, 2025

USD 10.8 Billion

Forecast, 2035

USD 20.66 Billion

CAGR, 2026-2035

6.7%

Report Coverage

United States

U.S. Contraceptive Market Trends for 2026

The U.S. contraceptive market size was estimated at USD 10.8 billion in 2025 and is predicted to increase from USD 11.52 billion in 2026 to approximately USD 20.66 billion by 2035, expanding at a CAGR of 6.7% from 2026 to 2035. The U.S. contraceptive market is growing due to its support for individuals to avoid unwanted pregnancies and plan births, which lowers pregnancy-related health challenges, specifically for adolescent girls.

Key Takeaways

• United States contraceptive market to crossed USD 11.52 billion by 2026.
• Market projected at USD 20.66 billion by 2035.
• CAGR of 6.7% expected in between 2026 to 2035.
• By product type, the hormonal contraceptives segment held 42% market share in 2025.
• By product type, the LARC segment held the second-largest market share of 25% in 2025, and is expected to grow at the fastest CAGR of 8.40% during the forecast period.
• By gender, the female segment held the largest market share of 78% in 2025.
• By gender, the male segment held the second-largest U.S. contraceptive market share of 22% in 2025, and is expected to grow at the fastest CAGR of 7.50% during the forecast period.
• By distribution channel, the retail pharmacies segment held the largest market share of 34% in 2025.
• By distribution channel, the online pharmacies segment held a market share of 18% in 2025, and is expected to grow at the fastest CAGR of 9.10% during 2026-2035.
• By end user, the clinics segment held the largest market share of 40% in 2025.
• By end user, the homecare settings segment held a notable market share of 28% in 2025 and is expected to be the fastest-growing with 7.80% CAGR during 2026-2035.

What is Supporting the Growth of the Contraceptive Market in the U.S.?

The U.S. contraceptive market is growing, as efficient contraception advantages both mothers and children through lessening morbidity and mortality, enhancing the social and economic status of women, and improving the relationship of the mother with her offspring. The United States has rates of unintentional pregnancy and abortion more approaching those of an emerging country than those of other industrialized nations. In the U.S., couples, 40% select male or female sterilization as their technique of contraception. Novel contraceptive methods probably to become available in the US soon will increase the number of efficient, reversible contraceptive choices for US couples. Increasing access to a wide variety of methods will increase contraceptive applications.

Pill Use Among Young Women in the U.S.

How is AI governing the U.S. Contraceptive Market?

AI-based technology integrated into sexual reproductive health, involving enhancing care, offering high-quality contraception and infertility solutions, removing unsafe abortions, and allowing the prevention and treatment of sexually transmitted infections. AI-based technology analyzes to understand trends in sexual behavior, contraceptive use, and attitudes toward reproductive health. Government spending in AI-based initiatives, through collaboration of public-private organizations and intended funding streams, improves sustainability and encourages broad adoption.

Future Outlook & Trends in the U.S. Contraceptive Market

Growth of Non-Hormonal Options:

Non-hormonal contraceptives are technologies that prevent pregnancy without intervening in the body’s hormonal cycle. Because they do not contain synthetic hormones like progestin or estrogen, they are used in women who cannot use hormonal contraceptives due to health reasons.

Rise in Male Contraception R&D:

The advancement of male contraception has been massively researched over the past few years. Different hormonal and non-hormonal technologies are being developed to offer better contraception with negligible or no disadvantages.

Dual-Protection Focus on Contraception:

A dual contraceptive technology is the utilization of any modern contraceptive technology along with male or female condoms, which decreases sexually transmitted diseases (STDs) and unwanted pregnancy.

Executive Summary Table

Segmentation Analysis

By Product Type Insights

Hormonal Contraceptives Segment Led the U.S. Contraceptive Market in 2025

The hormonal contraceptives segment contributed the largest market share of 42% in 2025, as hormonal contraceptives are efficient in preventing pregnancy; they contain a progestin, which inhibits ovulation. Hormonal contraceptives have been shown to offer different noncontraceptive advantages. Hormonal contraceptives reduce the risks of endometrial cancer, colorectal cancer, ovarian cancer, and osteoporosis.

The LARC segment held the second-largest share of 24% of the market in 2025 and is expected to grow at the fastest CAGR of 8.40% during the forecast period, as LARC offers an efficient process of contraception with lower compliance challenges by the consumer and prevents unwanted pregnancies and their challenges. These technologies are the most active modern contraceptive processes for preventing unintended pregnancy. They are long-acting, reliable, safe, and affordable.

Whereas the barrier methods segment held a notable share of 18% in the U.S. contraceptive market in 2025, as barrier contraception stops pregnancy by stopping the male's sperm from coming into contact with the female's ovum. Barrier contraceptives are affordable and convenient. Many women use them to avoid health challenges related to hormonal contraceptives.

The permanent methods segment held a notable share of 10% of the market in 2025, as permanent processes are more than 99% efficient at preventing pregnancy. Unlike short-term or long-acting processes, they never need to be renewed or replaced. Permanent contraception includes a surgical procedure that reliably prevents future pregnancies.

The emergency contraceptives segment held a notable share of 6% of the market in 2025, as emergency contraception is efficient when applied early, with only 3% of women becoming pregnant if used within 24 hours of unprotected sexual intercourse. Emergency contraception (EC) prevents up to over 95% of pregnancies when taken within 5 days after intercourse.

By Gender Insights

Female Segment Led the U.S. Contraceptive Market in 2025

The female segment contributed the largest market share of 78% in 2025, as female contraceptives provide significant benefits beyond pregnancy prevention, including highly efficient family planning, regulation of menstrual cycles, lower menstrual pain (dysmenorrhea), and reduced symptoms of PMS/PMDD.

The male segment held the second largest share of 22% of the U.S. contraceptive market in 2025 and is estimated to achieve 7.50% CAGR during 2026-2035, as male contraceptives lower the number of ejaculated fertile sperm inflowing the vagina to levels that reliably prevent fertilization. They have the strength to be simple to apply and reversible. Testosterone functions as a male contraceptive by suppressing the secretion of LH and FSH from the pituitary through negative feedback.

By Distribution Channel Insights

The Retail Pharmacies Segment held the Largest Share in the Market in 2025

The retail pharmacies segment contributed the largest market share of 34% in 2025, as retail pharmacies play an important role in medical providers by offering convenient access to medications, a broad range of products, and significant additional solutions. Retail pharmacies are a significant part of medical care systems and, in major countries, are responsible for dispensing a huge proportion of medical care products.

The hospital pharmacies segment held the second largest share of 28% of the U.S. contraceptive market in 2025, as hospital pharmacies supply drugs to other entities performing medical actions, inpatient facilities offering 24-hour medical services, or outpatient health solutions.

The clinics & public health programs segment held a notable share of 20% of the market in 2025, as the family planning (KB) program aims to enhance the welfare of a family by limiting the birth rate or number of children born. These programs not only avert unintended pregnancies, lowering maternal and infant mortality rates, but also offer significant, comprehensive care.

The online pharmacies segment held a notable share of 18% of the market in 2025 and is expected to be the fastest-growing segment with 9.10% CAGR, as online pharmacies often provide competitive pricing, discounts, and generic substitutes, leading to potential price savings for patients. This affordability is predominantly relevant for those with chronic conditions who need long-term medicine.

By End User Insights

The Clinics Segment held the Largest Share of the Market in 2025

The clinics segment contributed the largest market share of 40% in 2025, as enhanced contraceptive use, lowered unintended pregnancies, better birth spacing, increased prenatal care, lowered incidence of preterm and low-birthweight offspring, increased breastfeeding, increased HPV vaccinations, and cervical tumor screenings.

The hospitals segment held the second-largest share of 32% of the U.S. contraceptive market in 2025. It supports patients in avoiding unintended pregnancies and planned births, and it lowers pregnancy-related health challenges, specifically for adolescent girls. Efficient contraception advantages both mothers and children by lowering morbidity and mortality, enhancing the social and economic status of women.

Whereas the homecare settings segment held a notable share of 28% in the market in 2025 and is estimated to grow at the highest CAGR of 7.80% during the upcoming period, as this type of care increases the effectiveness of contraceptive use, which could lower the incidence of unintended pregnancies, and if provided after delivery, could decrease short-interval unintended pregnancy. Home visits remove the requirement for transport to clinics, decreasing both the expenses and time challenges.

Supply Chain Analysis

R&D:

• Research and development (R&D) for U.S. contraceptives involves discovery and basic research, target product profile, preclinical development, clinical trials, regulatory approval, product acceptance, and manufacturing and commercialization
• Key Players: Viatris Inc. and CooperSurgical, Inc. 

Manufacturing Processes:

• Manufacturing processes for contraceptives are significantly specialized, based on whether the product is a pharmaceutical, such as pills, injections, implants, or a barrier method like condoms or diaphragms.
• Key Players: Bayer AG and Pfizer Inc.

Patient Services:

• Patient services included in contraception are comprehensive, concentrating on voluntary, informed, and client-driven care to support patients in choosing, initiating, and continuing their progress.
• Key Players: Teva Pharmaceutical Industries and Organon

Latest Updates of Key Players in the U.S. Contraceptive Market

SWOT Analysis

Strengths

• The contraceptive implant works very well at preventing pregnancy. It's over 99% effective if applied correctly at the right time.
• Combination therapy in oral contraceptives lowers the risk of endometrial and ovarian cancer by around 50%. The risk of both carcinomas decreases with the growing duration of oral contraceptive use.

Weaknesses

• The significant adverse effects are spotting or bleeding between periods, sore breasts, headaches, or nausea.

Opportunities

• Advancement of intravaginal ring (IVR) technologies is allowing for newer approaches to include multiple drug moieties in a single device.
• Recent novelties in oral contraceptive pills (OCPs) focus on lowering adverse effects and improving user control. Significant advancements include low-dose/extended-cycle formulations, customization for conditions such as polycystic ovary syndrome (PCOS), and enhanced safety profiles. 

Threats

• Major consumers are experiencing noteworthy adverse effects, involving irregular bleeding, headaches, and mood swings, leading to high discontinuation rates.

Recent Developments in the U.S. Contraceptive Market

• In February 2026, NEXT Life Sciences, a leader in reproductive and sexual health companies, is revolutionizing the contraceptive category with two male birth control options that meet these needs, both in active clinical trials. Non-hormonal methods at the forefront of male interest have been long-acting, reversible options and temporary, on-demand solutions.
• In January 2026, Organon, a worldwide healthcare organization with a mission to deliver impactful medicines and services for a healthier each day, announced that the US Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for NEXPLANON, which is indicated for use by women of reproductive potential to prevent pregnancy.
• In December 2025, the Center for Reproductive Rights filed a lawsuit against the U.S. Department of State for refusing to offer data related to its plans to destroy at least $10 million of unexpired, taxpayer-funded contraceptives meant for low-income countries.
• In November 2025, Femasys Inc. announced a significant initial order valued at around $500,000 USD for the profitable launch of FemBloc Permanent Birth Control in France and the Benelux region via its partnership with leading distributor Kebomed.

Segments Covered in the Report

By Product Type

• Hormonal Contraceptives
• Oral Contraceptive Pills
  • Injectable Contraceptives
  • Transdermal Patches
  • Vaginal Rings
• Barrier Methods
  • Male Condoms
  • Female Condoms
  • Diaphragms
  • Cervical Caps
• Long-Acting Reversible Contraceptives (LARC)
  • Intrauterine Devices (IUDs)
    • Subdermal Implants
• Permanent Methods
  • Female Sterilization
  • Male Sterilization (Vasectomy)
• Emergency Contraceptives
  • Active Irrigation Sheaths 
  • Passive Irrigation Sheaths  

By Gender

• Female
• Male

By Age Group

• 15–24 Years
• 25–34 Years
• 35–44 Years
• 45+ Years

By Distribution Channel

• Hospitals
• Clinics
• Homecare Settings